Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals

We are a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies. 

Learn more about Synergy

Our Team

We have GI expertise and the commitment to develop and bring to market treatments that address the unmet needs of patients.

Learn more about Synergy's team

Plecanatide

Plecanatide is our lead uroguanylin analog currently in late-stage clinical development for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Learn more about plecanatide

Our Pipeline

Proprietary GI Platform Based on Uroguanylin

Plecanatide is our first uroguanylin analog in late-stage clinical development for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Dolcanatide is our second uroguanylin analog that has successfully completed a phase 2 study in patients with opioid induced constipation (OIC) and is currently being evaluated for the treatment of ulcerative colitis (UC).

Learn more about our pipeline
Compound Indication Phase 1 Phase 2 Phase 3 Market
Plecanatide
(sp-304)
CIC
IBS-C
DOLCANATIDE
(sp-333)
OIC
UC
Go To Investor Relations

Investor Relations

Overview

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.

Recent Documents

SGYP NASDAQ
Volume
Market Cap
Change